Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224

Benzinga · 3d ago
Guggenheim analyst Delma Caiati maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $207 to $224.